It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Giant cell lesions of the jaw (GCLJ) are debilitating tumors of unknown origin with limited available therapies. Here, we analyze 58 sporadic samples using next generation or targeted sequencing and report somatic, heterozygous, gain-of-function mutations in KRAS, FGFR1, and p.M713V/I-TRPV4 in 72% (42/58) of GCLJ. TRPV4 p.M713V/I mutations are exclusive to central GCLJ and occur at a critical position adjacent to the cation permeable pore of the channel. Expression of TRPV4 mutants in HEK293 cells leads to increased cell death, as well as increased constitutive and stimulated channel activity, both of which can be prevented using TRPV4 antagonists. Furthermore, these mutations induce sustained activation of ERK1/2, indicating that their effects converge with that of KRAS and FGFR1 mutations on the activation of the MAPK pathway in GCLJ. Our data extend the spectrum of TRPV4 channelopathies and provide rationale for the use of TRPV4 and RAS/MAPK antagonists at the bedside in GCLJ.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Gayden, Tenzin 2
; Bajic, Andrea 2
; Harraz, Osama F 3
; Pratt, Jonathan 2 ; Nikbakht, Hamid 4
; Bareke, Eric 4
; Marina Gonçalves Diniz 5
; Wagner Henriques Castro 5 ; St-Onge, Pascal 6 ; Sinnett, Daniel 7
; Han, HyeRim 8 ; Rivera, Barbara 9 ; Mikael, Leonie G 10 ; Nicolas De Jay 2 ; Kleinman, Claudia L 11 ; Valera, Elvis Terci 12
; Bassenden, Angelia V 13 ; Berghuis, Albert M 13 ; Majewski, Jacek 4
; Nelson, Mark T 14 ; Ricardo Santiago Gomez 15
; Jabado, Nada 16
1 Department of Human Genetics, McGill University, Montreal, QC, Canada; Department of Pathology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
2 Department of Human Genetics, McGill University, Montreal, QC, Canada
3 Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT, USA
4 Department of Human Genetics, McGill University, Montreal, QC, Canada; McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada
5 Department of Oral Surgery and Pathology, Faculty of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
6 CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada
7 CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada; Department of Pediatrics, University of Montreal, Montreal, QC, Canada
8 Lady Davis Research Institute, Jewish General Hospital, Montreal, QC, Canada
9 Lady Davis Research Institute, Jewish General Hospital, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
10 Department of Pediatrics, McGill University and McGill University Heath Centre Research Institute, Montreal, QC, Canada
11 Department of Human Genetics, McGill University, Montreal, QC, Canada; Lady Davis Research Institute, Jewish General Hospital, Montreal, QC, Canada
12 Department of Human Genetics, McGill University, Montreal, QC, Canada; Department of Pediatrics, Ribeirão Preto Medical School, Universidade de São Paulo, São Paulo, Brazil
13 Department of Biochemistry, McGill University, Montreal, QC, Canada
14 Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT, USA; Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK
15 Department of Human Genetics, McGill University, Montreal, QC, Canada; Department of Oral Surgery and Pathology, Faculty of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
16 Department of Human Genetics, McGill University, Montreal, QC, Canada; Department of Pediatrics, McGill University and McGill University Heath Centre Research Institute, Montreal, QC, Canada




